Carboplatin in refractory epithelial ovarian cancer
Kavanagh, J.J.; Nicaise, C.
Seminars in Oncology 16(2 Suppl 5: 45-48
1989
ISSN/ISBN: 0093-7754 PMID: 2655098 Document Number: 334800
Document emailed within 1 workday
Related Documents
Vapattanawong, P. 2006: A comparative study on hematological effects of carboplatin plus cyclophosphamide and carboplatin plus paclitaxel chemotherapy for the first line treatment of epithelial ovarian cancer Journal of the Medical Association of Thailand 89(9): 1357-1361Skarlos, D.V.; Aravantinos, G.; Kosmidis, P.; Athanassiadis, A.; Stathopoulos, G.P.; Pavlidis, N.; Bafaloukos, D.; Karphathios, S.; Papakostas, P.; Bamia, C.; Fountzilas, G. 1997: Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study Seminars in Oncology 24(5 Suppl 15: S15
Misawa, H.; Ochiai, K.; Yasuda, M.; Tanaka, T. 2004: Combination chemotherapy with docetaxel and carboplatin for epithelial ovarian cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 62(Suppl 10): 546-549
Ota, T.; Takeshima, N.; Takizawa, K. 2011: Second-line chemotherapy for carboplatin/paclitaxel-refractory ovarian cancer: are multi-agent chemotherapies of little value truly? European Journal of Gynaecological Oncology 32(5): 471-475
Kietpeerakool, C.; Tiyayon, J.; Suprasert, P.; Kanjanavanit, R.; Srisomboon, J. 2006: Benefit of electrocardiography during front-line combination paclitaxel and carboplatin chemotherapy for epithelial ovarian cancer Journal of the Medical Association of Thailand 89(11): 1805-1810
Satthapong, D.; Tangjitgamol, S.; Manusirivithaya, S.; Pataradool, K. 2007: Chemotherapy in patients with recurrent or refractory epithelial ovarian cancer Journal of the Medical Association of Thailand 90(3): 411-419
Thavaramara, T.; Tangjitgamol, S.; Manusirivithaya, S.; Leelahakorn, S. 2009: Oral etoposide for refractory or recurrent epithelial ovarian cancer Journal of the Medical Association of Thailand 92(11): 1397-1405
Bruzzone, M.; Chiara, S.; Falcone, A.; Graziani, G.; Conte, P.F.; Rosso, R. 1987: 4-Demethoxydaunorubicin (IMI-30) in refractory epithelial ovarian cancer: a pilot study Chemioterapia: International Journal of the Mediterranean Society of ChemoTherapy 6(2): 137-139
Wilailak, S.; Tresukosol, D.; Linasmita, V.; Termrungruanglert, W. 2000: Phase Ii study of high-dose paclitaxel in platinum-refractory epithelial ovarian cancer European Journal of Gynaecological Oncology 21(6): 610-612
Lehoczky, O.ó; Pulay, T.ás. 2003: Early results of first-line chemotherapy with paclitaxel and carboplatin in patients with epithelial ovarian carcinoma Orvosi Hetilap 144(28): 1381-1384
Du Bois, A.; Lück, H.J.; Meier, W.; Möbus, V.; Costa, S.; Richter, B.; Warm, M.; Bauknecht, T.; Schröder, W.; Olbricht, S.; Nitz, U.; Jackisch, C. 1997: Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase IIi trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group Seminars in Oncology 24(5 Suppl 15: S15
Ozols, R.F. 1999: Chemotherapy for ovarian cancer: beyond paclitaxel plus carboplatin Cancer Journal from Scientific American 5(6): 336-338
Ten Bokkel Huinink, W.; Veenhof, C.; Helmerhorst, T.; Bierhorst, F.; Dalesio, O.; Winograd, B.; Depauw, L.; Pinedo, H.M. 1995: Paclitaxel plus carboplatin in the treatment of ovarian cancer Seminars in Oncology 22(3 Suppl 6: 97-100
Ozols, R.F. 1999: Paclitaxel plus carboplatin in the treatment of ovarian cancer Seminars in Oncology 26(1 Suppl 2: 84-89
Kato, T.; Nishimura, H.; Yamabe, T.; Terashima, Y.; Kasamatsu, T.; Hirabayashi, K.; Nishiya, I.; Yajima, A.; Takamizawa, H.; Tsutsui, F. 1988: Phase Ii study of carboplatin in ovarian cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(8): 2291-2296
Kietpeerakool, C.; Suprasert, P.; Srisomboon, J. 2005: Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer Journal of the Medical Association of Thailand 88(3): 301-306
Miglietta, L.; Cannobbio, L.; Boccardo, F. 1995: Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity Anticancer Research 15(6b): 2825-2828
Jin, Z.; Gu, J.; Xin, X.; Li, Y.; Wang, H. 2014: Expression of hexokinase 2 in epithelial ovarian tumors and its clinical significance in serous ovarian cancer European Journal of Gynaecological Oncology 35(5): 519-524
Jacobs, I.J.; Smith, S.A.; Wiseman, R.W.; Futreal, P.A.; Harrington, T.; Osborne, R.J.; Leech, V.; Molyneux, A.; Berchuck, A.; Ponder, B.A. 1993: A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus Cancer Research 53(6): 1218-1221
Ohno, M.; Hirokawa, M.; Hando, T. 1992: Pharmacokinetics of carboplatin after intraperitoneal administration and clinical effect in ovarian cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 19(14): 2355-2361